MindBio Therapeutics (XCNQ:MBIO) Net Cash per Share : C$-0.04 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). MindBio Therapeutics's Net Cash per Share for the quarter that ended in Mar. 2024 was C$-0.04.

The historical rank and industry rank for MindBio Therapeutics's Net Cash per Share or its related term are showing as below:

XCNQ:MBIO's Price-to-Net-Cash is not ranked ^*
in the Biotechnology industry.
Industry Median: 4.11
* Ranked among companies with meaningful Price-to-Net-Cash only.

MindBio Therapeutics Net Cash per Share Historical Data

The historical data trend for MindBio Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Net Cash per Share Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Net Cash per Share

-0.03

-0.04

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial					-0.03	-0.04	-0.04	-0.04	-0.04

Competitive Comparison of MindBio Therapeutics's Net Cash per Share

For the Biotechnology subindustry, MindBio Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Price-to-Net-Cash falls into.

MindBio Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

MindBio Therapeutics's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

	Net Cash per Share (A: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.298	-	5.433	-	-0.055)	/	133.047
=	-0.04

MindBio Therapeutics's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.231	-	5.272	-	-0.045)	/	133.047
=	-0.04

MindBio Therapeutics (XCNQ:MBIO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

MindBio Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.